Abstract
Introduction
The indirect effects of the COVID-19 pandemic on clinical practice have received great attention, but evidence regarding thyroid disease management is lacking. We aimed to investigate the association between delayed follow-up visits during the pandemic and their serum thyrotropin (TSH) levels among patients being treated with levothyroxine.
Methods
This study included 25,361 patients who made a follow-up visit as scheduled (n=9,063) or a delayed follow-up visit (<30 days, n=10,909; ≥30 days, n=5,389) during the pandemic (after April 2020) in Japan. We employed modified Poisson models to estimate the adjusted risk ratio (aRR) of TSH >4.5 and >10 mIU/L during the pandemic according to the three types of follow-up visit group (i.e., as scheduled, delayed <30 days, and delayed ≥30 days). The models included age, sex, city of residence, TSH levels, underlying thyroid disease, dose of levothyroxine, and duration of levothyroxine prescriptions.
Results
The mean age was 52.8 years and females were 88%. Patients who were older and had a higher dose or longer duration of levothyroxine prescriptions were more likely to make a delayed follow-up visit during the pandemic. Changes in TSH were larger among the delayed visit groups than the scheduled visit group. We found increased risks of elevated TSH levels during the pandemic among the delayed visit groups, particularly those with delayed visit ≥30 days (TSH >4.5 mIU/L, aRR [95% CI] =1.72 [1.60-1.85]; and TSH >10 mIU/L, aRR [95% CI] =2.38 [2.16-2.62]).
Conclusion
A delayed follow-up visit during the COVID-19 pandemic was associated with less well-controlled TSH among patients with levothyroxine.